The document discusses why London is an attractive location for life sciences businesses, highlighting its large life sciences sector, world-class universities and research institutions, supportive government policies and funding, strong talent pool, and collaborative environment including incubators, research centers like the Francis Crick Institute and Cell Therapy Catapult, and institutions supporting clinical trials and commercialization. London has over 1,000 life sciences companies and is a leader in areas like pharmaceuticals, biotechnology, and medical technology.
The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and other therapies is accelerated.
The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and other therapies is accelerated.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
London & Partners MedCity Cell & Gene Therapy Report londonandpartners
The golden triangle & Japan, natural collaborators in cell and gene therapy. Discover Cambridge, London and Oxford’s thriving life sciences ecosystem and cell and gene therapy expertise. The golden triangle offers clinical trials capabilities, a diverse population and single healthcare system, all supported by a committed government. Collaborate with us and help develop the next generation of cell and gene therapy treatments.
VR與AR技術於醫療領域的可能性及案例分析 (VR & AR Technologies in Medical Applications)宇軒 黃
【跨 X 創 產業小聚】#6
VR技術引爆超世代教學革新:從醫療與教育出發
VR and AR Technologies in Medical Applications
據美國研究機構報告,AR/VR的醫療健康市場到2020年將達25.4億美元,主要來自模擬訓練及康復治療。在未來的健康醫療教育融入虛擬及擴增實境應用中,又可以達到什麼境界?
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
London & Partners MedCity Cell & Gene Therapy Report londonandpartners
The golden triangle & Japan, natural collaborators in cell and gene therapy. Discover Cambridge, London and Oxford’s thriving life sciences ecosystem and cell and gene therapy expertise. The golden triangle offers clinical trials capabilities, a diverse population and single healthcare system, all supported by a committed government. Collaborate with us and help develop the next generation of cell and gene therapy treatments.
VR與AR技術於醫療領域的可能性及案例分析 (VR & AR Technologies in Medical Applications)宇軒 黃
【跨 X 創 產業小聚】#6
VR技術引爆超世代教學革新:從醫療與教育出發
VR and AR Technologies in Medical Applications
據美國研究機構報告,AR/VR的醫療健康市場到2020年將達25.4億美元,主要來自模擬訓練及康復治療。在未來的健康醫療教育融入虛擬及擴增實境應用中,又可以達到什麼境界?
Artificial intelligence (AI) is everywhere, promising self-driving cars, medical breakthroughs, and new ways of working. But how do you separate hype from reality? How can your company apply AI to solve real business problems?
Here’s what AI learnings your business should keep in mind for 2017.
Presentation of Simon Howell (Founding Non-Executive Director of MedCity and Guy’s Campus Dean at King’s College London King’s College London) at the Forum of the BioRegion of Catalonia, organized by Biocat.
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
Brochure | Case Reports Conference 2018 | London,UK | May 28-29 Ashley M. Benjamin
Euroscicon Ltd proudly presents the “8th International Conference on Clinical and Medical Case Reports, 2018” to be held on May 28-29, 2018 at London, UK.
This year’s theme is “Clinical and Medical Case Reports that pave way for an advanced healthcare”
Please visit the Conference website for more details : http://casereports.euroscicon.com/
Royal Veterinary College Business and International Engagement PresentationHorseTechConference
Slides to accompany the keynote talk by Tas Gohir, Head of Knowledge Transfer and Impact, Royal Veterinary College.
This presentation was delivered as the final keynote at the inaugural HorseTech Conference on the 18th October 2017 hosted by the Royal Veterinary College London.
10 Best Locations for Lifesciences Jobs in the World | The Lifesciences MagazineThe Lifesciences Magazine
Demand for life science specialists with expertise in multiple worldwide markets is rising as the globalization of the sector continues and the need for novel medical solutions skyrockets.
Dr Liz Mear, Chief Executive of the Innovation Agency presented at NHS Confed 17 about the NHS’ role in growing local economies and how Academic Health and Science Networks (AHSNs) can generate economic growth in life sciences through their role as catalysts, connectors and collaborators by spreading innovation, advancing health technology and improving healthcare
Similar to Imagine your life sciences business in London (20)
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
2. WHY LONDON FOR LIFE
SCIENCES
In 2011, pharmaceuticals, medical biotechnology and
medical technology sectors together comprise around
4,500 firms, employing 165,000 staff, with an R&D
spend of nearly £5bn and an annual turnover of over
£50bn
Life sciences manufacturing, which accounts for 8% of
the UK total (by GVA) remains important for the UK’s
growth. The pharmaceuticals sector alone accounts
for more UK-based business R&D than any other
manufacturing sector (accounting for over 28% of all
business R&D)
Over 300 pharmaceutical companies are based in the
UK and employ nearly 78,000 people, with an annual
turnover of £31bn. The medical technology and
medical biotechnology sectors represent over 4,000
companies employing 87,000 people with an annual
turnover of around £18.4bn
3. WHY LONDON FOR LIFE
SCIENCES
More progressive regulatory environment
that not only supports innovation, but
openly promotes it
London benefits from £16bn of public
sector healthcare, research and teaching
spend annually, with further funding
committed by the government
London is home to nearly 1,000
companies in life sciences, and more
than 8,000 in healthcare
4. THE RIGHT ENVIRONMENT
London is the most accessible city in the world, from both a
travel and time-zone viewpoint
London has more than 40 universities with 1,300 biomedical
researchers and five world class medical schools and 12
teaching hospital, more than 50 clinical institutions with a
huge patient population for clinical trials
Hospitals: patients, research & research facilities, with access
to a diverse and concentrated population through NHS patient
records
London’s life sciences offering is growing with the set up of
the Francis Crick Institute and the Cell therapy catapult
centre, both in central location and easy to access
The London Stock Exchange (LSE), with its Alternative
Investment Market is, increasingly, the public market of choice
for European biotechs
London provides easy access to VCs and service providers,
including lawyers, accountants, and public relations
consultants, which biotechs require to build their businesses
Presence of additional funding bodies e.g., The Wellcome
Trust, Medical Research Council, and Imanova
5. THE RIGHT ENVIRONMENT
Incubator space:
• London BioScience Innovation Centre (LBIC)
• Imperial Bio-incubator: based in South Kensington, the aim of
this £7m incubator space is to bring valuable ideas to market
either by building businesses or licensing to industry
• Queen Mary Bio Enterprises in Whitechapel: a £28m and
39,000 square feet capacity building, providing state of the art
London laboratory and office space
Home to the Medicines and Healthcare products Regulatory
Agency (MHRA) and European Medicine Agency (EMEA)
Availability of laboratory and office space in the London BioScience
Innovation Centre (LBIC) next to St Pancras Station in central
London (biotechnology, life science product and diagnostic
companies, contract research organisations, medical device
companies and service providers operating in the same space)
Universities are increasingly collaborating on commercial
opportunities: offering access to academics, students and
laboratories to companies
Host to headquarters of 2 of the top 10 global Pharma companies
(GSK and AZ), with high levels of research activity e.g., AZ
invested over £1.1 bn in UK R&D
Host to R&D centres of other international biotechnology
companies e.g., Amgen’s international R&D HQ in UK
6. GOVERNMENT SUPPORT
Government commitments:
Injection of £100m in universities research facilities from
2012/13 with aim to attract further co-investment from private
sector
Launch of the UKRMP (UK Regenerative Medicine Platform),
a £25m cross research council fund
Supportive tax and regulatory environment:
Patent box: 10% corporate tax on profits derived from patents
(new and existing)
R&D tax relief: 225% tax relief available to SMEs, 130% to
large companies
Commitment from government and charities to fund research
and commercial applications:
£130m in stratified medicine
£60m over 3 years to fund researchers to work on treatments
for chronic diseases
£60m over 4 years to collaborations between academia &
industry to further develop stratified medicine
Technology Strategy Board (TSB) initiatives: Cell Therapy
Technology Innovation Centre, a catapult centre for
regenerative medicine, and the BioMedical Catalyst fund, a
£180 m initiative set up in collaboration with the Medical
Research Council
7. UNIQUE TALENT POOL
The UK accounts for 11% of the world‟s citations in biological
sciences and has a long history of breakthroughs discoveries (e.g.:
Alexander Fleming discovering the penicillin in 1928)
World class universities: London has seven universities in the Times
Higher Education world top 200 university rankings – more than any
other city in the world
Nobel prizes: as of 2010, there were 72 Nobel prizes laureates
affiliated to the University of London, 26 affiliated to UCL. London
claims 14 Nobel Prize winners in Medicine and Physiology, and 25
overall in sciences
39,404 research papers are generated in London, second only to
Boston (50,106)
2011/2012: 45,000 domestic students in medicine subjects + 5,000
foreign students; 14,000 domestic graduates + 2,500 foreign
graduates
Access to university talent and resources through Knowledge
Transfer Partnerships (KTPs): 60% funded by grants, the aim is to
encourage knowledge transfer through collaboration with business
environment
The Medical Research Council committed £70million to support PhD
students and 320 posts across the UK; while the National Institute for
Health Research (NIHR) is to support 1,600 research training posts
Funding form from charities such as The Wellcome Trust & Cancer
Research UK
Recruitment of foreign scientists made easier by new regulation:
several entry routes possible (guest lecturer, external examiner, intra-
company transfer)
9. IMAGING
COLLABORATIVE ENVIRONMENT:
IMANOVA CASE STUDY
Imanova partnership (www.imanova.co.uk):
Collaboration between the Medical Research
Council, Imperial College, University College
and King’s College
Objective to provide a state of the art imaging
research facility to develop new applications
(current strengths are on cancer and
neurosciences)
Collaboration with British life sciences
company GSK, which transferred its imaging
capabilities in London
London to become a national hub for imaging
facilities and collaboration between academic
and commercial institutions
11. CLINICAL TRIALS
National Institute for Health Research (NIHR) to help clinical trials
company by facilitating access to the NHS capabilities, with record
investment of £800m over 5 years from 2012:
NIHR Office for Clinical Research (NOCRI) helps companies to
find experts to support their studies
NOCRI establishes a communication link between companies
and the NIHR
Network providing delivery of the studies in the NHS &
assistance in seeking approval to run the medical trials
Provides technical support and access to expertise through
biomedical research centres (Universities & NHS partners).
King’s College is developing an informatics system to support
this initiative
Support from government with simplification of clinical trials approval
times
Adoption of the Academic Health Science Centres (AHSC) model, with
Imperial, King’s College and UCL already partners; the objective is to
accelerate the research developments into applications benefiting the
patients
The London AHSC are exploring the idea to create information
systems using NHS information to allow for large groups of patients to
take part into global clinical research
As well as big-name clinical research organisations including Quintiles
and Parexel, London is home to specialist CROs such as Pharmidex,
William Harvey Research Ltd and Cerebrion
13. HEALTHCARE
The total UK private healthcare¹ market by sector by value reached
£30.4bn in 2010, a 19.5% increase on 2006 value
Health, social care and special education services are a major focus of
economic activity in the UK, and currently accounts for 11.1% of UK GDP
The growing demand for healthcare, given the population ageing and the
increasing privatisation of healthcare (due to the increasing pressure on
NHS capacity) insulated the sector from recession
Government allowing private medical companies to carry NHS
treatments: trend towards outsourcing is forecasted to grow
As a result, opportunities in long term care (driven by elderly population)
and acute care (short term active treatment) are likely to increase in the
next few years
Potential for innovation and convergence: better quality of living, smart
houses / e-healthcare: London as the hub in tech innovation and
financial community to fund applications
Opportunities for VC and PE to become more involved in the market and
help accelerate growth
The marketplace includes big players such as Atos Healthcare, AXA PPP
Healthcare, Barchester Healthcare, but the majority are small and
medium-sized providers
Private Medical Insurance: currently less than a third of British residents
are thought to have private insurance², in majority men & women aged
35-54 (41%), form social classes A and B (59% of respondents); Over a
third are residing in the Greater London & South East areas (37.2%)
15. CELL THERAPY CATAPULT
CENTRE
The global commercial cell therapy industry was estimated to
have an annual turnover of $1bn in 2011, is forecast to grow to
$5bn by 2014, with even greater growth predicted beyond that
Due to be launched in end of 2012, the Cell Therapy Catapult
centre will be an autonomous entity, independent of higher
education institutions, that will play a significant role in speeding
up development and accelerating routes to market
£50m over 5 years committed from research councils, the
National Institute for Health Research (NIHR) and the
Technology Strategy Board (TSB), with £10m per year
investment
Offering state of the art laboratories and offices in St Guy’s
Hospital, central London
Collaboration between academics, businesses and clinicians to
focus on the commercial development of cutting-edge
technologies in regenerative medicine clinical offerings
Current developments include Julie Daniels' limbal cell grafts at
the Institute of Ophthalmology, UCL as well cell & gene therapy
combinations at the Great Ormond Street hospital
Cell therapy players in London and immediate surroundings
include Cell Medica, ReNeuron (now in clinical phase)
16. THE FRANCIS CRICK INSTITUTE
Due to be launched in 2015, the objectives of
the biomedical science research institute
are:
to generate new insights and knowledge
about the biological mechanisms controlling
cell, tissue and body function
through collaboration, to find ways to
prevent and drive forward better treatment
of the most significant diseases affecting
people
Consortium of academic & scientific
institutions:
The Medical Research Council (biomedical
research)
Cancer Research UK (cancer charity)
The Wellcome Trust (charitable foundation)
University College London
Imperial College London
King's College London
18. ONE NUCLEUS
Commercial, clinical and academic powerhouse for
international life science and healthcare companies formed in
2010 by the merger of two regional life science networks –
Cambridge-based ERBI and the London Biotechnology Network
(LBN)
Promoting collaboration between Cambridge and London
thus tapping onto the heart of Europe’s largest life science and
healthcare cluster;
London and Cambridge are home to at least 60% of the
UK’s life science industry base, four of the UK’s five
Academic Health Science Centres and three of the world’s
top six universities
The institute’s mission is to improve the global competitiveness of
its members by:
Giving access to a large pool of companies and thus
supporting business-to-business interaction
Providing visibility to members through a cluster of
international size and relevance
Providing discounted entry to events in London and
Cambridge
Allowing for economies of scale supporting a group
purchasing scheme
Providing a training programme focused on the needs of
the members
19. LONDON BIOSCIENCE
INNOVATION CENTRE (LBIC)
Owned by the Royal Veterinary College, it hosts over
35 biotechnology and life science companies in
central London, including small start-ups and more
established players
Tenants include biotechnology, life science product
and diagnostic companies, contract research
organisations, medical device companies and
service providers
Provides laboratory and office facilities of high
standard and a professional front door a short walk
from St Pancras International and the site of the new
UK Centre for Medical Research and Innovation
(UKCMRI)
Clients benefit from shared networking space and
meeting rooms as well as close proximity to the
various financial services available throughout
London.
An experienced management team in building and
supporting biotechnology businesses
20. LONDON REGENERATIVE
MEDICINE NETWORK (LRMN)
Over 6,000 members from the general
public, patients, patient
groups, politicians, students, scientists, clinici
ans, engineers, industrialists, funding
agencies, regulators and the media
Forum for new regenerative medicine
technologies to be presented and discussed
via monthly meetings
Committed to helping facilitate the building of
a competitive and sustainable international
cell and gene therapy industry in the UK
Facilitated collaborations and the launch of
the Regenerative Medicine journal to
accelerate delivery of safe, efficacious
therapies that can be affordably
manufactured at scale for use in routine
clinical practice
21. UK REGENERATIVE MEDICINE
PLATFORM (UKRMP)
In Sept 2012, the Biotechnology and Biological Sciences Research
Council (BBSRC), Engineering and Physical Science Research
Council (EPSRC) and Medical Research Council (MRC) launched a
£25m UK Regenerative Medicine Platform (UKRMP) to address
the technical and scientific challenges associated with translating
promising scientific discoveries in this area towards clinical impact
Objectives:
interdisciplinary and complementary research hubs to promote
the development of regenerative therapies
Part of the broader UK research strategy seeking to support
high quality UK research activity and translational activity that
will help deliver the great promise of regenerative medicine to
the benefit of both patients and future economic growth
BBSRC, EPSRC and MRC are inviting proposals to establish high
quality, collaborative research groupings to address key
challenges in translational regenerative medicine
The five main themes (hubs) of research are:
1. Cell behaviour, differentiation and manufacturing;
2. Engineering and exploiting the stem cell niche;
3. Safety and efficacy, focussing on imaging technologies;
4. Acellular (smart material) approaches for therapeutic delivery;
5. and Inducing immune tolerance
22. COLLABORATIVE ENVIRONMENT:
ACCESS TO UNIVERSITIES
Imperial Bio-incubator www.imperialinnovations.co.uk:
A £7m incubator space based in South Kensington, to bring valuable ideas to market either by
building businesses or licensing to industry
Queen Mary Bio Enterprises in Whitechapel www.qmbioenterprises.com:
A £28m and 39,000 square feet capacity building, providing state of the art London laboratory and
office space, and access to world class clinical, teaching and research resources (Royal London
Hospital nearby)
Providing support for new ventures and being a hub for entrepreneurial activity. Tenants located at
the Innovation Centre can benefit from opportunities to access the facilities available at the world
class London School of Medicine Dentistry; access to the university business support network and
investors events; and leverage Queen Mary technical and commercialisation experience in the
healthcare and biotechnology sectors
Knowledge transfers www.ktponline.org.uk:
KTP is a programme run by the Technology Strategy Board (TSB), a partnership between a
University, a graduate and a company/organisation with a strategic need that could be solved via
knowledge transfer
Recruitment of a graduate to work on a knowledge transfer project from 6 months to 3 years to help
unlock a company’s potential
Available to a wide range of sectors and partly funded by the government (covering 60% of costs for
SMEs; up to 50% for larger organisations). Growth potential by over 40% for participants
A large amount of KTP funding remains unallocated in 2012. At a recent workshop held by the TSB it
was announced that good project applications are needed urgently as the money must be spent this
year
23. FINANCIAL INCENTIVES TO
DYNAMISE THE ECOSYSTEM
Seed Enterprise Investment Scheme (SEIS www.seis.co.uk):
Governmental scheme to help small and early stage UK-based start-
ups: companies must employ less than 25 people and must have
assets of less than £200,000. Benefits:
50% income tax relief on investments
Capital gains tax exemption on gains (from sale of asset)in
2012/2013 financial year if investment in the SEIS the same
year
Enterprise Capital Funds www.capitalforenterprise.gov.uk (£300m)
and Business Angel Co-Investment fund www.angelcofund.co.uk
(£50m): to finance innovative SMEs with high growth potential
Commitment to invest £180m in 2012-2014 to support discovery,
development and commercialisation of research:
Funds allocated by the MRC www.mrc.ac.uk & the TSB
Biomedical Catalyst fund
www.innovateuk.org/content/competition/biomedical-catalyst
In August 2012, University College London (£700,000),
Imperial College (£700,000) and King’s College London
(£500,000) received funds to transform early stage research
ideas into commercial applications
A further £130m to invest in later stage development
25. UK LIFE SCIENCES STRATEGY
Build an integrated ecosystem promoting collaboration
between companies and research institutes
Easy commercialisation of academic research:
Encouraging knowledge transfers from academia to
businesses
Find Kinston initiative – it does exist at national level
and is sanctioned by gvt (funded); Technology
transfer office Imperial Innovations at Imperial
College
Contributions by public and charity funding to
accelerate research and therefore contribute to
products developments
Clinical research as innovation driver within the NHS:
The government announced £800 m in clinical
research over the next 5 years (new NIHR Biomedical
Research centres and partnerships to boost research
in cancer, dementia, ageing conditions, etc.)
Resource finder point offers up to date information
about knowledge and technologies by location,
research topic, skills and equipment
The UK as a place to deliver life sciences innovation
26. JAPANESE BASED PHARMACEUTICAL COMPANY SHIONOGI & CO., LTD
LAUNCHED ITS NEW EUROPEAN HEADQUARTERS IN LONDON. SHIONOGI
ELECTED TO BASE THEIR EUROPEAN HEADQUARTERS IN LONDON FOLLOWING
AN EXTENSIVE REVIEW OF POTENTIAL LOCATIONS.
“WE ARE DELIGHTED TO BE LAUNCHING OUR
NEW EUROPEAN HEADQUARTERS IN LONDON -
WE AIM TO ACHIEVE OUR MISSION AS A COMPANY
WITH A STRONG PRESENCE IN EUROPE
TAKASHI EAKENOSHITA
”
CEO OF SHIONOGI EUROPE
27. HOW LONDON & PARTNERS
CAN HELP YOUR BUSINESS
SUCCEED
28. THE EXPERTS ON DOING BUSINESS IN LONDON
HOW WE CAN HELP YOU SET UP
BUSINESS
FIND THE
PROPERTY
FIND THE
BUSINESS FIND THE EXPAND YOUR YOUR
&PROPERTY
LOCATION
CASE RIGHT PEOPLE NETWORK LONDON
& LOCATION
- Sector Intelligence - Specialist Recruitment - Office Specialists - Professional Service - Culture & Social Life
- Legal Requirements - Funding & Training - Market, Clients & -- Events - Visas & Work Permits
- Corporate/Tax Structure - Salary Benchmarking Transport -- Government Contacts - Schools & Colleges
- Cost-effective Set-up - Employment Practice - Labour Pool -- Policy-makers
- Demographic Mapping
WWW.LONDONANDPARTNERS.COM/IMAGINEYOURBUSINESS
BUSINESS@LONDONANDPARTNERS.COM
@L_PBUSINESS JOIN US ON LINKEDIN: „LONDON & PARTNERS FDI GROUP‟
UK 11% of citations: BIS, Strategy for UK life sciencesResearch papers: McKinsey report – London Life SciencesNobel prizes sources: 14 in medicine from London-based institutions & 25 overall science: http://www.nobelprize.org/nobel_prizes/lists/universities.html; 72 laureates & 26 at UCL: http://en.wikipedia.org/wiki/List_of_Nobel_laureates_affiliated_with_University_College_London#Medicine.2FPhysiologyFunding & Immigration: BIS, Strategy for UK Life sciences
Source: BIS, Strategy for UK Life Scienceshttp://www.imanova.co.uk/
Source: UKTI, UK Life Sciences, Discovering today: transforming tomorrow, 2011Source: BIS, strategy for UK Life sciencesLondon AHSC: Imperial, King’s Health Partners, UCL PartnersCROs list: London & Partners
¹ Definition of healthcare as defined by Laing & Buisson (KeyNote report, 2011 Healthcare): It includes direct privately-paid revenue sources, such as private medical insurance (PMI) and primary care, as well as the acute care sector, where a small but significant percentage of fees are paid via National Health Service (NHS) outsourcing. Also included is the market for long-term residential and nursing care for the elderly, as well as care for the mentally ill and adults with learning difficulties. The market size, as estimated in this chapter, includes revenue from private individuals, as well as some funding from public healthcare and social care budgets. http://spike/Document%20Repository/Key%20Note%20Private%20Healthcare%202011.pdf (page 10)Source UK GDP: The Role of Private Equity in UK Health & Care Services July 2012; http://www.laingbuisson.co.uk/Portals/1/Media_Packs/Fact_Sheets/LB_PrivateEquity_2012.pdf Source government outsourcing: The Role of Private Equity in UK Health & Care Services July 2012; http://www.laingbuisson.co.uk/Portals/1/Media_Packs/Fact_Sheets/LB_PrivateEquity_2012.pdf ²Private insurance stats methodology: survey conducted by Target Group Index (TGI) between 2010 and 2011 on a sample size of 49,920 people, only 15.8% of respondents were found to have personal private medical insurance (PMI), while a further 11.6% revealed that other member of their household had PMI. The more affluent groups, particularly those living in the South East, were clearly the main users of private healthcare services, including PMI, with penetration dropping rapidly beyond social grade C2. Penetration was the lowest in the North of the country. By age group, penetration peaked among the 35 to 44 year-olds, with usage declining gradually with age thereafter. Source: http://spike/Document%20Repository/Key%20Note%20Private%20Healthcare%202011.pdf Definition acute care: branch of secondary health care where a patient receives active but short-term treatment for a severe injury or episode of illness, an urgent medical condition, or during recovery from surgery. In medical terms, care for acute health conditions is the opposite from chronic care, or longer term care.Acute care services are generally delivered by teams of health care professionals from a range of medical and surgical specialties. Acute care may require a stay in a hospital emergency department, ambulatory surgery centre, urgent care centre or other short-term stay facility, along with the assistance of diagnostic services, surgery, or follow-up outpatient care in the community.Hospital-based acute inpatient care typically has the goal of discharging patients as soon as they are deemed healthy and stable.[3] Acute care settings include but are not limited to: emergency department, intensive care, coronary care, cardiology, neonatal intensive care, and many general areas where the patient could become acutely unwell and require stabilization and transfer to another higher dependency unit for further treatment.
Source: https://catapult.innovateuk.org/cell-therapySource commercial revenues and growth: https://catapult.innovateuk.org/cell-therapy Cell therapy describes the process of introducing new cells into a tissue in order to treat a disease. Cell therapies often focus on the treatment of hereditary diseases, with or without the addition of gene therapy. Cell therapy is a sub-type of Regenerative Medicine.'Regenerative medicine' is the replacement or regeneration of human cells, tissues or organs to restore or establish normal function (2). It includes cell therapies, gene therapies, tissue engineering and biomedical engineering techniques. (http://www.bionews.org.uk/page_169246.asp, Dr E. Culme-Seymour)Stem cell: a cell that can multiply and give rise to a variety of other, more specialised cell types. For example, stem cells in the bone marrow make many different blood cells. (Source: idem)Examples of collaborations and player: Emily Culme Seymour
Source: http://www.crick.ac.uk/
Source: http://www.crick.ac.uk/
Source: http://www.onenucleus.com/One Nucleus is the legal entity for the Council of European Bio Regions (www.cebr.net)
Source Imperial bioincubator: http://www.imperialinnovations.co.uk/incubatorSource Queen Mary Bio Enterprises: http://www.qmbioenterprises.com/Source A large amount of KTP funding remains unallocated in 2012. At a recent workshop held by the TSB it was announced that good project applications are needed urgently as the money must be spent this year, Kingston university newsletter, 2 Oct 2012.More on KTP in medicine: https://connect.innovateuk.org/web/healthktn
Source: BIS, Strategy for UK Life Sciences AND http://www.hm-treasury.gov.uk/d/seed_enterprise_investment_scheme.pdfECF: The current ECFs are: Amadeus Enterprise Fund, Catapult Growth Fund, Dawn ECF, IQ Capital Fund, MMC Ventures ECF, Oxford Technology ECF, Panoramic Growth Equity, Seraphim ECF and the Sustainable Technology Fund, Notion Capital, Passion Capital (source: http://www.bbc.co.uk/news/business-12049304 and http://www.bis.gov.uk/policies/enterprise-and-business-support/access-to-finance/enterprise-capital-funds)
Source: https://catapult.innovateuk.org/cell-therapySource commercial revenues and growth: https://catapult.innovateuk.org/cell-therapy Cell therapy describes the process of introducing new cells into a tissue in order to treat a disease. Cell therapies often focus on the treatment of hereditary diseases, with or without the addition of gene therapy. Cell therapy is a sub-type of Regenerative Medicine.'Regenerative medicine' is the replacement or regeneration of human cells, tissues or organs to restore or establish normal function (2). It includes cell therapies, gene therapies, tissue engineering and biomedical engineering techniques. (http://www.bionews.org.uk/page_169246.asp, Dr E. Culme-Seymour)Stem cell: a cell that can multiply and give rise to a variety of other, more specialised cell types. For example, stem cells in the bone marrow make many different blood cells. (Source: idem)Examples of collaborations and player: Emily Culme Seymour
http://www.londonandpartners.com/media-centre/press-releases/2012/120706-shionogi-launches-new-european-headquarters-in-londonFriday 06 July 2012Japanese based pharmaceutical company Shionogi & Co., Ltd (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi” or “the Company”) has launched its new European Headquarters in London, United Kingdom, to be called “Shionogi Limited”. The new headquarters will form a new era for the Company as it expands its global business into Europe.As part of the 3rd Medium-Term Business Plan, a five year plan to expand its business world wide, Shionogi will bring a long standing reputation to Europe. Dating back from 1878, the Company has been involved in research, development, manufacturing and marketing activities for over 130 years and is very proud to be a part of the European pharmaceutical community.Shionogi elected to base their European Headquarters in London following an extensive review of potential locations on the Continent as well as within the UK. London was chosen by Shionogi because of the good business infrastructure and support, the pool of exceptional talent, a favourable living environment for their employees and easy access to the rest of Europe. “We are delighted to be launching our new European Headquarters in London.” said Takashi Eakenoshita, CEOof Shionogi Europe. “We aim to achieve our mission as a company with a strong presence in Europe, which conducts business operations recognised by patients, their families, healthcare providers and broader communities.”The Mayor of London, Boris Johnson, added “Boosting jobs and growth is my number one priority, and this means attracting ever more companies to the capital. Shionogi will make a fantastic addition to London's growing life sciences sector, which benefits from our top class universities and research centres, direct access to huge markets, a skilled cosmopolitan workforce, and fantastic connectivity. London really is the best place in the world to do business, something I will be taking every opportunity to showcase throughout this summer like no other.”Shionogi has a strong heritage in the discovery and development of globally important therapies. In 1998 Shionogi licenced one of its new molecules that later became Crestor® (generic name: rosuvastatin calcium) to AstraZeneca, and still markets this drug in Japan today. Currently the Company has a strong strategic focus on infectious diseases, pain and metabolic syndrome.The Company plans to quickly expand the number of employees in London and has recently made several key appointments: Dr Marco Renoldi, Dr SuhailNurbhai, Dr Mark Sampson, Nina Strenitz and Joe Gaugas.Shionogi marked its launch in Europe with a prestigious event in central London attended by key members of the pharmaceutical and healthcare industries, with talks from Lord Darzi of Denham PC KBE FMedSciHonFREng, (Imperial College London), Mr Martin Donnelly (Permanent Secretary for Business, Innovation and Skills ), Mr Kit Malthouse (Deputy Mayor for Business and Enterprise) Professor Andrea Genazzani, MD, PhD, FRCOG, (Professor of Obstetrics and Gynaecology, University of Pisa, Italy), Professor Brian Gazzard, CBE (Chelsea and Westminster Hospital, London) and Mr Isao Teshirogi, President and CEO of Shionogi.